Sustaining the gains in cancer care from the oncology care model.

Authors

Valerie Csik

Valerie P Csik

Sidney Kimmel Cancer Center, Philadelphia, PA

Valerie P Csik , Jared Minetola , Andrew E. Chapman , Neal Flomenberg

Organizations

Sidney Kimmel Cancer Center, Philadelphia, PA, Thomas Jefferson University, Philadelphia, PA

Research Funding

Other Government Agency

Background: The Oncology Care Model (OCM) is a 5-year demonstration project led by the Centers for Medicare and Medicaid Services (CMS) to create a framework for the future of oncology care in the United States. More than half way through the project, our large, urban NCI-designated cancer center chose to focus on and invest in resources and personnel for patient navigation and the development of clinical pathways. Although navigation has shown to reduce emergency department (ED) visits by as much as 6% per quarter compared to non-navigated patients, sustaining it is a challenge because it is a nonbillable service. Clinical pathways are a tool to reduce care variation by addressing drug expenditures, and represent an opportunity to reduce outpatient costs by as much as 35% when patients are treated on pathway.3 Many OCM practices made similar investments and all are facing the question: How will the infrastructure and efforts developed during OCM be sustainable after the demonstration project ends?Methods: An analysis of average ED cost and utilization as well as drug expenditures was conducted using OCM feedback data (Q1-Q8). Total utilization of ED visits and ED admits were used to determine a projected annualized cost which was compared to a budgeted navigation team. Similarly, projected annualized drug expenditures were compared to the annual cost of the pathways tool. Results: We found that ED visits and ED admits would need to be reduced by 11% to cover navigation costs. Similarly, a 0.7% reduction in total drug expenditures would cover the cost of clinical pathways. The OCM data represents a timeframe prior to implementation of these programs and an average increase of 1.6% per quarter for ED admits, a 0.6% decrease in ED visits and 2.7% increase in drug expenditures. This will serve as a baseline to measure progress towards our sustainability targets. Conclusions: Long term sustainability of the infrastructure developed during OCM to support cancer care transformation will be dependent on reducing high cost and highly utilized services. Aligning impact areas with resources/tools to ensure sustainability is an approach that can help define targets for OCM practices.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Health Services Research, Clinical Informatics, and Quality of Care

Track

Quality Care/Health Services Research

Sub Track

Value/Cost of Care

Citation

J Clin Oncol 37, 2019 (suppl; abstr 6632)

DOI

10.1200/JCO.2019.37.15_suppl.6632

Abstract #

6632

Poster Bd #

323

Abstract Disclosures

Similar Abstracts

First Author: Chetan Vakkalagadda

Abstract

2019 ASCO Quality Care Symposium

Pathways impact on OCM drug cost.

First Author: Valerie Pracilio Csik

First Author: Andrew Allan Hertler